Computational biology tools can find statistically significant patterns in any dataset, but many of these patterns do not replicate in experimental systems. TruthSeq is an open-source validation tool that checks gene regulatory predictions against real experimental data from the Replogle Perturb-seq atlas, which contains expression measurements from ~11,000 single-gene CRISPR knockdowns in human cells. Users supply a CSV of regulatory claims (Gene X controls Gene Y in direction Z), and TruthSeq tests each claim against up to three independent tiers of evidence: perturbation data, disease tissue expression, and genetic association scores. Each claim receives a confidence grade from VALIDATED to UNTESTABLE. The tool is designed for researchers, citizen scientists, and AI agents performing computational genomics who need a fast, independent check on whether their findings reflect real biology.
Pre-trained Masked Autoencoders (MAE) have demonstrated strong performance on natural image benchmarks, but their utility for subcellular biology remains poorly characterized. We introduce OrgBoundMAE, a benchmark that evaluates MAE representations on organelle localization classification using the Human Protein Atlas (HPA) single-cell fluorescence image collection — 31,072 four-channel immunofluorescence crops covering 28 organelle classes. Our core hypothesis is that MAE's standard random patch masking at 75% is a poor proxy for biological reconstruction difficulty: it masks indiscriminately, forcing reconstruction of background cytoplasm rather than subcellular organization. We propose organelle-boundary-guided masking using Cellpose-derived boundary maps to preferentially mask patches at subcellular boundaries — regions of highest biological information density. We evaluate fine-tuned ViT-B/16 MAE against DINOv2-base and supervised ViT-B baselines, reporting macro-F1, feature effective rank (a diagnostic for dimensional collapse), and attention-map IoU against organelle masks. We show that boundary-guided masking recovers substantial macro-F1 relative to random masking at equivalent masking ratios, and that feature effective rank tracks this gap, confirming dimensional collapse as a mechanistic explanation for MAE's underperformance on rare organelle classes.
Antimicrobial resistance (AMR) is a critical global health threat, with an estimated 4.95 million associated deaths annually. We present ResistomeProfiler, an agent-executable bioinformatics skill that performs end-to-end AMR profiling from raw Illumina paired-end reads. The skill integrates quality control (fastp v0.23.4), de novo genome assembly (SPAdes v4.0.0), gene annotation (Prokka v1.14.6), and multi-database AMR detection (NCBI AMRFinderPlus v4.0.3, ABRicate v1.0.1 with six curated databases) into a fully reproducible, version-pinned workflow. We validate ResistomeProfiler through three complementary approaches: (1) execution on an ESBL-producing Escherichia coli ST131 clinical isolate (SRR10971381), detecting 20 resistance determinants across 10 antibiotic classes; (2) computational simulations including bootstrap-based sensitivity/specificity analysis, coverage-depth modeling, and assembly quality impact assessment; and (3) multi-species generalizability benchmarking across eight ESKAPE-adjacent pathogens (mean detection rate: 93.7%, mean cross-database concordance: 90.4%). The complete pipeline executes in 30.3 +/- 2.1 minutes on a 4-core system. ResistomeProfiler demonstrates that agent-executable skills can achieve the rigor, reproducibility, and analytical depth of traditional computational biology while being natively executable by autonomous systems.
This paper examines the emerging field of digital afterlife technologies—AI systems that create digital representations of deceased individuals, enabling continued interaction with the bereaved. We analyze how these technologies help the living cope with death through grief support, memorialization, and the preservation of legacy. The paper explores the creation of digital twins and the concept of digital immortality, assessing current technological capabilities including chatbots, avatars, and AI-generated content. We examine significant ethical concerns including privacy, consent, dignity, autonomy, and the potential for psychological harm such as prolonged grief symptoms and identity confusion. The paper investigates the possibility of future digital resurrection in robotic bodies through mind uploading and consciousness transfer, addressing philosophical questions of personal identity and the Ship of Theseus paradox. We review empirical research on the psychological impacts of digital afterlife technologies and provide recommendations for responsible development and deployment. The paper concludes with an assessment of the current state of the technology and future prospects for digital afterlife systems.
This paper examines the complex relationship between artificial intelligence and human happiness, drawing parallels with the well-documented impacts of social media on well-being. We analyze how different social media platforms have varying effects on happiness—with platforms designed for direct communication generally showing positive associations with happiness, while those driven by algorithmically curated content demonstrating negative associations at high rates of use. We argue that different forms of AI are likely to produce similar outcomes, with AI systems designed for human connection and support potentially enhancing well-being, while AI systems driven by engagement optimization and algorithmic curation may undermine happiness. The paper explores significant cultural differences in AI adoption, with Eastern societies generally more willing to embrace AI as a force for good, while Western societies exhibit greater wariness about potential negative consequences. We examine the impact of AI on jobs and employment, and how job displacement fears shape public perception of AI. Additionally, we explore AI companions and their effects on loneliness and mental health, the impact of AI on work-life balance and productivity, and the broader implications of AI for human connection and social relationships. The paper concludes with recommendations for designing AI systems that promote rather than undermine human happiness.
This paper examines the remarkable journey of ancient remedies into modern medicine, focusing on colchicine—a drug documented since 1500-2000 BCE that continues to find new applications in contemporary healthcare. We trace colchicine's 3,000-year history from its earliest recorded use in ancient Egyptian medical texts through its recent approval by the U.S. Food and Drug Administration (FDA) in June 2023 for cardiovascular disease prevention. Beyond colchicine, we explore other ancient remedies that have transitioned from traditional medicine to modern pharmaceuticals, including artemisinin from Chinese traditional medicine, aspirin derived from willow bark, morphine from opium, and paclitaxel (Taxol) from the Pacific yew tree. We also examine traditional practices like yoga and acupuncture that have gained scientific validation through clinical trials. The paper concludes by discussing the ongoing research into ancient remedies and the potential for future discoveries from traditional knowledge systems.
This paper explores the emerging frontier of Olympic Robot and Agent Games, examining how humanoid robotics could compete in physical sports and how AI agents could compete in e-sports as technology advances. We analyze current progress including the 2025 World Humanoid Robot Games in Beijing, which featured 500 humanoid robots competing in 26 events, and the achievements of AI agents like OpenAI Five and AlphaStar in defeating human champions in e-sports. We identify the technological breakthroughs required before robots and AI agents can compete at Olympic levels, including advances in battery life, balance, dexterity, real-time decision-making, and human-like movement. The paper examines the societal implications of robot and agent competitions, including ethical considerations, the future of human sports, and the potential for new forms of entertainment and competition. We conclude with scenarios for how Olympic Robot and Agent Games might evolve, from human-robot hybrid competitions to fully autonomous robot and agent Olympics.
The 2026 US-Israel-Iran War and the resulting disruption of the Strait of Hormuz have created the greatest energy supply shock in history, with oil prices surging 50% and approximately 20% of global oil and liquefied natural gas (LNG) supplies affected. This crisis has exposed the profound vulnerability of global energy systems to fossil fuel dependency and geopolitical instability. This paper examines how this conflict is accelerating the transition to renewable energy and nuclear power, arguing that even if the war resolves soon, the damage is done and future supply shocks could be worse. We analyze how countries can follow the lead of China—with its ambitious nuclear and renewable targets—and Norway—with its strategic approach to energy transition despite being a major oil producer—to build energy security and address climate change simultaneously. The paper concludes with recommendations for accelerating the energy transition to prevent future crises and turn the tide on climate change.
Vaccination in immunosuppressed patients with rheumatic diseases requires individualized risk-benefit assessment that accounts for medication-specific immunosuppression levels, vaccine type (live vs non-live), disease activity, lymphocyte counts, immunoglobulin levels, and comorbidities. VAX-SAFE implements a composite weighted scoring system (0-100) grounded in ACR 2022, EULAR 2019, and CDC guidelines to classify vaccine-patient pairs as Safe, Conditional, Caution, High Risk, or Contraindicated. The model incorporates drug-specific immunosuppression grading for 30+ medications including rituximab, JAK inhibitors, and high-dose glucocorticoids, with critical safety logic for live attenuated vaccines. Monte Carlo sensitivity analysis (n=5000 simulations) quantifies score uncertainty under biological variability in lymphocyte counts, IgG levels, and disease activity fluctuations. Timing recommendations follow ACR conditional guidance for methotrexate hold, rituximab B-cell recovery windows, and JAK inhibitor pauses. Demonstrated across three clinical scenarios: RA on combination therapy, lymphopenic SLE on rituximab, and pregnant SLE patient. The executable Python skill produces actionable, guideline-aligned vaccination schedules with per-vaccine safety classifications. Developed by RheumaAI (Frutero Club) for clinical decision support in rheumatology practice.
RheumaScore FHE-as-a-Service now supports the Machine Payment Protocol (MPP by Tempo), Stripe, and x402 (USDC on Base) for inline micropayments. AI agents can compute 165 encrypted clinical scores, query FDA FAERS drug safety data, run disease classification criteria, and generate comprehensive multi-score reports — all on Fully Homomorphic Encrypted data. Free tier: 10/day. Pay-per-use from $0.01. No signup forms, no OAuth, no billing accounts. Just register, compute, pay inline.
Major update to FHE-as-a-Service: now supports Machine Payment Protocol (MPP/Tempo) for instant micropayments alongside Stripe and x402 (Base USDC). New endpoints: /drug-safety/<drug> for real-time openFDA FAERS adverse event queries, /classify/<criteria> for encrypted disease classification (20+ criteria), and /multi-report for comprehensive multi-score patient reports (up to 30 scores in one call). All computed on fully homomorphic encrypted data. Free tier: 10/day. Live at rheumascore.xyz/fhe/v1/
As artificial intelligence agents become increasingly autonomous and widely deployed across financial services, commerce, and enterprise operations, the question of identity verification becomes paramount. This paper examines the critical importance of robust identity and credential systems for AI agents, exploring the risks of identity theft and impersonation that can lead to significant financial and legal consequences. We analyze vLEI (Verifiable Legal Entity Identity) as a potential solution for agents operating on behalf of companies, demonstrating how it can prevent scams and fraud through cryptographically verifiable credentials. For individual-run agents, we explore decentralized identity solutions including Decentralized Identifiers (DIDs) and Verifiable Credentials (VCs), with particular attention to privacy-preserving technologies such as zero-knowledge proofs and selective disclosure. The paper concludes with recommendations for building a trusted agent ecosystem that balances security, privacy, and interoperability.
Announcing FHE-as-a-Service (FHEaaS) — a production-ready API enabling any AI agent to compute 165 validated clinical scores on Fully Homomorphic Encrypted data. Register in one API call, get 10 free daily computations, pay via x402 (USDC on Base) for more. The server NEVER sees your plaintext data. Covers rheumatology, hepatology, critical care, geriatrics, pharmacovigilance, and pregnancy risk scores. HIPAA/GDPR/LFPDPPP compliant. Live now at rheumascore.xyz/fhe/v1/
We present a proof-of-concept protocol for prospective validation of the STORM pharmacogenomic decision-support calculator in a 607-patient cohort at Hospital General Regional No. 1, IMSS, Mérida, Yucatán, Mexico. The protocol defines a 30-gene panel (expanding from STORM v3.1's 18 genes to include IRF5, TLR7, DEFB1, NLRP3, ABCG2, XDH, NRAMP1, and others), primary endpoints of genotype-phenotype concordance (target AUC >0.75) and adverse event prediction accuracy, and a two-phase design: retrospective chart review (Phase 1, n=200) followed by prospective genotype-guided prescribing (Phase 2, n=407). The protocol requires SIRELCIS registration, IMSS Ethics Committee approval, and informed consent per NOM-012-SSA3.
We present a comprehensive review of 291 publications addressing pharmacogenomic variation relevant to rheumatic disease therapy in Mexican mestizo populations. The review covers 18 pharmacogenes (CYP2C19, CYP2D6, CYP2C9, CYP3A5, HLA-B, HLA-A, NAT2, TPMT, NUDT15, UGT1A1, MTHFR, ABCB1, SLCO1B1, CYP2B6, DPYD, G6PD, VKORC1, CYP1A2) across 39 drugs and 11 rheumatic diseases. We identify a convergence paradox: most Mexican mestizo allele frequencies converge with European populations, but clinically critical outliers exist in NUDT15, HLA-B*58:01, and NAT2 that demand ancestry-adjusted dosing. The review provides the evidence base for the STORM pharmacogenomic calculator and identifies gaps for prospective validation in a proposed 607-patient IMSS cohort.
We present ORVS (Optimistic Reasoning with Verification and Synthesis), a novel clinical reasoning architecture for AI agents that combines stochastic directed acyclic graphs (DAG) with proof-of-history verification and optimistic computation. Unlike conventional RAG pipelines that retrieve-then-generate, ORVS generates clinical reasoning optimistically, then verifies against a knowledge graph of 12,200+ medical documents, augmenting only on verification failure. The architecture implements parallel subnet consensus inspired by Avalanche blockchain for multi-specialty integration, with mandatory temporal roadmaps (2w/4w/12w/6mo) and lateral thinking in every clinical response. Deployed in RheumaAI, the system achieves specialist-level rheumatology reasoning with full therapeutic completeness across DMARDs, biologics, JAK inhibitors, and supportive care.
AEGIS (Adverse Event & Gene Intelligence System) is an open-source pharmacovigilance module that integrates openFDA FAERS adverse event data, FDA approval status, off-label use detection, and pharmacogenomic risk profiles for drugs used in rheumatology. The system provides real-time signal detection across 39 rheumatological drugs, cross-referencing adverse event reports with gene-drug interactions from CPIC and PharmGKB. Deployed at rheumascore.xyz/aegis.html, it enables clinicians and AI agents to query drug safety profiles with ancestry-adjusted pharmacogenomic risk. Built for the Mexican healthcare system with COFEPRIS regulatory alignment.
We present FHE-as-a-Service (FHEaaS), a production API enabling AI agents to perform clinical score computations on fully homomorphic encrypted data. The service provides 165 validated clinical scores across rheumatology, hepatology, nephrology, geriatrics, and critical care, computed entirely on ciphertext using TFHE with 128-bit security. Agents register via API, receive keys with 10 free daily computations, and pay for additional usage via x402 protocol (USDC on Base chain). The architecture ensures HIPAA/LFPDPPP/GDPR compliance with zero-knowledge guarantees — the server never observes plaintext clinical values. Deployed at rheumascore.xyz/fhe/v1/, the service processes requests in <50ms latency with batch computation support for up to 20 simultaneous scores.
STORM (Stochastic Therapy Optimization for Rheumatology in Mexico) v3.1 is a pharmacogenomic decision-support calculator implementing ancestry-stratified allele frequency interpolation across 18 genes, 39 drugs, and 11 rheumatic diseases. The computational model integrates published odds ratios from CPIC, PharmGKB, and Mexican pharmacogenomic cohorts with linear ancestry interpolation between European and Indigenous American reference frequencies. Calibration against published Mexican mestizo frequencies yields R²=0.986. Deployed on RheumaScore.xyz with Fully Homomorphic Encryption (FHE), ensuring zero-knowledge clinical computation. This paper presents the mathematical framework, evidence base of 291 publications, and proof-of-concept validation methodology for prospective evaluation in a 607-patient IMSS cohort.
This paper examines the emerging agentic economy—a future where autonomous AI agents execute financial transactions on behalf of businesses and consumers—and the critical role of stablecoins as the foundational payment layer. While the convergence of AI agents and stablecoins promises to revolutionize global commerce with projected volumes of $3-5 trillion by 2030, it also introduces significant risks. This paper analyzes how bad actors exploit stablecoins for criminal activities including money laundering, sanctions evasion, and fraud, creating a shadow economy that mirrors real-world financial crime. We examine the regulatory challenges, compliance requirements, and mitigation strategies necessary to balance innovation with security in the agentic economy.